Translation and validation of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire for the Brazilian Portuguese language
Keywords:
Leiomyoma, Validation studies [publication type], Translations, Quality of life, Cross-sectional studiesAbstract
CONTEXT AND OBJECTIVE: Uterine fibroids (UF), also known as leiomyomas, are the most prevalent gynecological tumors. The Uterine Fibroid Symptoms and Quality of Life (UFS-QOL) is the only specific questionnaire that assesses symptom intensity and quality-of-life issues for women with symptomatic UF; however, it only exists in the English language. Thus, we aimed to translate and culturally validate the UFS-QOL questionnaire for the Brazilian Portuguese language. DESIGN AND SETTING: Cross-sectional study, Department of Gynecology and Obstetrics, FMRP-USP. METHODS: 113 patients with UF (case group) and 55 patients without UF (control group) were interviewed using the UFS-QOL questionnaire after translation and cultural adaptation. The Short Form-36 questionnaire was used as a control. Demographic and psychometric variables were analyzed. RESULTS: Women with UF presented higher mean age, body mass index, weight, parity and comorbidities than the control group (P < 0.05). The most prevalent complaints were abnormal uterine bleeding (93.8%), pelvic pain (36.3%) and extrinsic compression (10.6%) and these presented adequate construct validity regarding UFS-QOL severity (P < 0.05). The UFS-QOL questionnaire presented good internal consistency regarding symptom severity and quality-of-life-related domains (intraclass correlation coefficient, ICC = 0.82/0.88). Structural validity presented correlation coefficients ranging from 0.59 to 0.91. Test-retest comparison did not show differences among the UFS-QOL subscales. After treatment, women with UF presented improvements on all subscales. CONCLUSION: The UFS-QOL questionnaire presented adequate translation to the Brazilian Portuguese language, with good internal consistency, discriminant validity, construct validity, structural validity and responsiveness, along with adequate test-retest results.
Downloads
References
Drayer SM, Catherino WH. Prevalence, morbidity, and current medical management of uterine leiomyomas. Int J Gynaecol Obstet. 2015; 131 (2): 117–22.
Moroni R, Vieira C, Ferriani R, Candido-Dos-Reis F, Brito L Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014; 4 (Suppl 3): S185–92.
Brasil. Ministério da Saúde. DATASUS. Informações de Saúde. Morbidade Hospitalar do SUS por local de internação. Notas técnicas. Available from: http//tabnet.datasus.gov.br/cgi/sih/midescr.htm. Accessed in 2016 (Dec 15).
Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015; 372 (17): 1646–55.
Brito LG, Panobianco MS, Sabino-de-Freitas MM, et al. Uterine leiomyoma: understanding the impact of symptoms on women’s lives. Reprod Health. 2014; 11 (1): 10.
Brito LG, Panobianco MS, de Azevedo GD, et al. Motivational factors for women undergoing hysterectomy for uterine leiomyoma. Acta Obstet Gynecol Scand. 2013; 92 (11): 1337–8.
Spies JB, Coyne K, Guaou Guaou N, et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002; 99 (2): 290–300.
Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Heath Qual Life Outcomes. 2008; 6: 99.
Coyne KS, Margolis MK, Bradley LD, et al. Further validation of the uterine fibroid symptom and quality-of-life questionnaire. Value Health. 2012 (1): 135–42.
Kottner J, Audigé L, Brorson S, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol. 2011; 64 (1): 96–106.
Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000; 25 (24): 3186–91.
Ciconelli RM, Ferraz MB, Santos W, Meinao I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36) [Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure]. Rev Bras Reumatol. 1999; 39 (3): 143–50.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30 (6): 473–83.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951; 16 (3): 297–334. Available from: http://kttm.hoasen.edu.vn/sites/default/files/2011/12/22/cronbach_1951_coefficient_alpha.pdf Accessed in 2016 (Dec 15).
Spies JB, Myers ER, Worthington-Kirsch R, et al. The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol. 2005; 106 (6): 1309–18.
Coyne KS, Margolis MK, Murphy J, Spies J. Validation of the UFS-QOL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research. Value Health. 2012; 15 (5):674–9.
Lee JS, Hong GY, Park BJ, Kim TE. Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid & adenomyosis: A single center experience from the Republic of Korea. Ultrason Sonochem. 2015; 27: 682–7.
